

A sample article title for the "Cesk Patol" journal

Nowak J.¹, Nowakov H.^{1,2}, Smith J.C.³

¹*Department of Pathology, King's College London, London, UK*

²*Department of Pathology, Charles University, Prague, Czech Republic*

³*Department of Oncology, Institute of Sciences, Stanford CA, USA*

Corresponding author:

Name, Titles

Department, Institution

Mail Address, City, ZIPcode

State, Country

Phone number, Fax number

Email address

Introduction starts without a heading, XXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXXXXX XX

x. (1) XXXXXXXXXXX XXXXXX

XXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X
XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXXXXX XX X (2,3).

XXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X
XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXXXXX XX X.

XXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX (4-7) XXXXXXXXXXXXXXXXXXXXXXX X X XXXXX
XXXXXXXXXX X XX.

MATERIALS AND METHODS

XXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X
XX

XXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X
XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXXXXX XX X (clone A2, LabVision Co.)

XXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X
XX

XXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X
XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXXXXX XX X.

RESULTS

Subheading (level 2 - bold)

Subheading (level 3 - bold + italics)

Subheading (level 4 - italics)

xx xxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxx xx x (Fig. 1). Xxxxxx xxxxxxxxxxxxxxxxxxx
 xxxxxxxxxxx xx x (Fig. 2A). Xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxxxxx
 xxxxxxxxxxxxxxxxxxx x x xxxxx xxxxxxxxxxx x xx
 xxxxxxxxxxxxxxxxxxx x x xxxxx xxxxxxxxxxx x xx (Fig. 2B) xxxxxx xxxxxxxxxxxxxxxxxxx
 xxxxxxxxxxx xx x. xxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxx xx x (Tab. 1).

In the Table 2 xxxxxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx x x xxxxxx
 xxxxxxxxxxx x xx xxxxxx xx x.

DISCUSSION

Subheading (level 2 - bold)

Subheading (level 3 - bold + italics)

Subheading (level 4 - italics)

Xxxxxxxx (2) xxxxxx xxxxxxxxxxx xxxxxxxxxxx (3,7) xxxxxxxxxxxxxxxxxxx x x xxxxxx
 xxxxxxxxxxx x xx xxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxx xx x. Xxxxxxxx xxxxxx
 xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx x x xxxxx xxxxxxxxxxx x (xx xxxxxx
 xxxxxxxxxxxxxxxxxxx xxxxxxxxxxx xx x.

Xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx (8-10) x x xxxxxx
 xxxxxxxxxxx x xx xxxxxx xxxxxxxxxxxxxxxxxxx xxxxxxxxxxx (1, 2-4) xx x.

Xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx x x xxxxx xxxxxxxxxxx x

ACKNOWLEDGEMENTS

Text of Acknowledgements.

REFERENCES

1. **Galizia E, Giorgetti G, Piccinini G, Santinelli A, Loretelli C, Bianchi F, et al.** BRCA1 expression in triple negative sporadic breast cancers. *Anal Quant Cytol Histol.* 2010; 32(1): 123-129.
2. **Glinoeer D.** Thyroid disease during pregnancy. In: **Braverman LE, Utiger RE,** eds. *Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text* (8th ed). Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 1013–1027.
3. **Stevens A, Lowe J.** *Pathology* (2nd edn). Mosby: London; 2000: 224–226.
4. **Baselga J, Rothenberg ML, Tabernero J.** TGF- β 1, pSMAD and TGF β -related markers in patients with advanced metastatic cancer. *Proc Natl Acad Sci USA.* In press 2011.
5. xxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx
6. xxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx
7. xxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx
8. xxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx
9. xxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx
10. xxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx

Table 1

Description xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx

	n	xx	xx	xxx
A	3	10	5	p < 0.001
B	4	10	5	p < 0.001
C	5	10	5	p < 0.001

n, number of patients

Cesk Patol

Table 2

Description xxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxx

	n	xx	xx	xx
D	3	10	5	p < 0.001
E	4	10	5	p < 0.001
F	5	10	5	p < 0.001

n, number of patients

Cesk Patol

FIGURE LEGEND

Fig. 1. Figure legend text. XXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXX

XXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXX XX

X XXXXXXXX X XX XXXXXXX.

Fig. 2. Figure legend text. XXXXXXXXXXX XXXXXX XXXXXXXXXXX XXXXXXXX

XXXXXXXXXXXXXXXXXXXX X X XXXXX XXXXXXXXXXX X XX XXXXXX XXXXXXXXXXXXXXXXXXX XXXXXXXX XX

X XXXXXXXX X XX XXXXXXX.

Cesk Patol